Rhythm Pharmaceuticals, Inc. (RYTM): Price and Financial Metrics
RYTM Price/Volume Stats
| Current price | $23.31 | 52-week high | $34.99 |
| Prev. close | $23.23 | 52-week low | $15.50 |
| Day low | $22.86 | Volume | 522,600 |
| Day high | $23.79 | Avg. volume | 691,965 |
| 50-day MA | $23.31 | Dividend yield | N/A |
| 200-day MA | $22.42 | Market Cap | 1.33B |
RYTM Stock Price Chart Interactive Chart >
RYTM POWR Grades
- RYTM scores best on the Growth dimension, with a Growth rank ahead of 27.71% of US stocks.
- The strongest trend for RYTM is in Growth, which has been heading down over the past 179 days.
- RYTM ranks lowest in Stability; there it ranks in the 5th percentile.
RYTM Stock Summary
- The ratio of debt to operating expenses for RHYTHM PHARMACEUTICALS INC is higher than it is for about merely 4.75% of US stocks.
- RYTM's price/sales ratio is 31.91; that's higher than the P/S ratio of 95.64% of US stocks.
- As for revenue growth, note that RYTM's revenue has grown 226.38% over the past 12 months; that beats the revenue growth of 97.26% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to RHYTHM PHARMACEUTICALS INC, a group of peers worth examining would be LGVN, PGEN, TFFP, CYCN, and VECO.
- RYTM's SEC filings can be seen here. And to visit RHYTHM PHARMACEUTICALS INC's official web site, go to www.rhythmtx.com.
RYTM Valuation Summary
- In comparison to the median Healthcare stock, RYTM's price/sales ratio is 697.5% higher, now standing at 31.9.
- Over the past 72 months, RYTM's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for RYTM.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| RYTM | 2023-09-18 | 31.9 | 7.7 | -7.7 | -7.5 |
| RYTM | 2023-09-15 | 32.5 | 7.8 | -7.8 | -7.6 |
| RYTM | 2023-09-14 | 32.1 | 7.7 | -7.7 | -7.5 |
| RYTM | 2023-09-13 | 32.0 | 7.7 | -7.7 | -7.5 |
| RYTM | 2023-09-12 | 33.5 | 8.0 | -8.0 | -7.9 |
| RYTM | 2023-09-11 | 33.5 | 8.1 | -8.1 | -7.9 |
RYTM's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- RYTM has a Quality Grade of F, ranking ahead of 2.46% of graded US stocks.
- RYTM's asset turnover comes in at 0.004 -- ranking 418th of 681 Pharmaceutical Products stocks.
- EVOK, ATRA, and EVFM are the stocks whose asset turnover ratios are most correlated with RYTM.
The table below shows RYTM's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.004 | 0.728 | -0.232 |
| 2021-06-30 | 0.001 | 0.544 | -0.211 |
| 2021-03-31 | 0.000 | 0.886 | -0.196 |
| 2020-12-31 | 0.000 | NA | -0.922 |
| 2020-09-30 | 0.000 | NA | -0.718 |
| 2020-06-30 | 0.000 | NA | -0.784 |
RYTM Price Target
For more insight on analysts targets of RYTM, see our RYTM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $36.67 | Average Broker Recommendation | 1.71 (Moderate Buy) |
Rhythm Pharmaceuticals, Inc. (RYTM) Company Bio
Rhythm Pharmaceuticals, Inc. develops and commercializes peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States. Its lead product candidate is Setmelanotide, a melanocortin-4 receptor agonist that is in Phase III clinical trials for treating POMC deficiency obesity and leptin receptor deficiency obesity; and Phase II clinical trials for treating Bardet-Biedl syndrome, Alström syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders. The company was founded in 2008 and is based in Boston, Massachusetts.
Latest RYTM News From Around the Web
Below are the latest news stories about RHYTHM PHARMACEUTICALS INC that investors may wish to consider to help them evaluate RYTM as an investment opportunity.
Rhythm Pharmaceuticals Presents New Data at ESPE 2023BOSTON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced four oral presentations at the 61st Annual European Society for Paediatric Endocrinology (ESPE) Meeting being held September 21-23, 2023 in The Hague, Netherlands. “We are excited |
Rhythm’s obesity therapy granted EU backing for orphan designationMore on Rhythm Pharma |
Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic ObesityBOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that the European Medicines Agency (EMA) has issued a positive opinion on the Company’s orphan drug designation request for setmelanotide as a treatment for acquired hypothalamic |
Companies Like Rhythm Pharmaceuticals (NASDAQ:RYTM) Are In A Position To Invest In GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
EVP Jennifer Lee Sells 6,166 Shares of Rhythm Pharmaceuticals Inc (RYTM)On September 5, 2023, Jennifer Lee, the Executive Vice President and Head of North America at Rhythm Pharmaceuticals Inc (NASDAQ:RYTM), sold 6,166 shares of the company. |
RYTM Price Returns
| 1-mo | -9.76% |
| 3-mo | 32.97% |
| 6-mo | 35.52% |
| 1-year | 8.12% |
| 3-year | -2.67% |
| 5-year | -13.63% |
| YTD | -19.95% |
| 2022 | 191.78% |
| 2021 | -66.43% |
| 2020 | 29.49% |
| 2019 | -14.58% |
| 2018 | -7.50% |
Loading social stream, please wait...